

References

Adler S.G., Cohen A.H., and Glassock R.J. (1995): "Glomerular involvement in multisystem diseases". In: The Kidney, 5th edit. Brenner B.M.(editor). W.B. Saunders Co.; Vol.(2): 1498- 1516.

Alarcón-segovia D., Estanol B., Garcia- Ramos G., and Villa A.R. (1997): Antiphospholipid antibodies and the antiphospholipid syndrome: Clinical relevance in neuropsychiatric systemic lupus erythematosus. Ann. N. Y. Acad. Sci.; 823: 279.

Al-Herz A., Schulzer M., and Esdaile J.M. (2002): Survey of antimalarial use in lupus pregnancy and lactation. J. Rheumatol.; 29(4): 700- 706.

Anderson R.D., and Clair E.W.S. (1998): The cardiovascular manifestations of rheumatic diseases. In: " Comprehensive Cardiovascular Medicine". Edited by: Topol E.J.; Lippincott-Roven, Philadelphia, New York.; Chap. 35: 1018.

Atkinson J.P., and Schifferli J.A. (1999): Complement system and systemic lupus erythematosus. In Kammer G.M. and Tsokos G.C. (eds): Lupus: Molecular and cellular pathogenesis. Totowa, N.J., Humana Press, P. 529.

- Bae S.C., Fraser P., and Liang M.H. (1998):** The epidemiology of systemic lupus erythematosus in populations of African Ancestry. *Arthritis & Rheum.*; 41(12): 2091- 2099.
- Blank m. and Shoenfeld y. (2005):** Experimental models of systemic lupus erythematosus: anti-dsDNA in murine lupus. *Rheumatology* 44(9):1086-1089.
- Bansal V.K., and Beto J.A. (1997):** Treatment of lupus nephritis: A meta- analysis of clinical trials. *Am. J. Kidney Dis.*; 29: 193.
- Barr, W.G. and Merchut, M.P. (1992):** Systemic lupus erythematosus with central nervous system involvement. *Ann rheum Dis.*, 49: 249-253.
- Boumpas DT,Fessler BJ,Austin III HA,Balow JE,,Klippel JH,and Lockshin MD.(1995):**Systemic lupus erythematosus :emerging concepts.Part 2.*Ann Intern Med.*;123:42-53.
- Bruyn G.A.W. (1995):** Controversies in lupus nervous system involvement. *Ann. Rheum. Dis.*; 54: 159- 167.
- Byrd S., Radkowski M. and Darling C. (1998):** Neuroimaging adjuncts to MRI: MRA/MRS/CINE MR CSF flow and analysis. *The Child's Doctor, Journal of Children's Memorial Hospital, Chicago.*

- Cabotte, R.M.; Denburg, S.D. and Denburg, J.A. (1986):** Prevalence of cognitive impairment in systemic lupus erythematosus. *J Nerv Ment Dis.*, 174: 357-364.
- Calabrese, L.V. and Stern, T.A. (1995):** Neuropsychiatric manifestations of systemic lupus erythematosus. *Psychosomatics*, 36: 344-359.
- Callen J.P. (2002):** Management of skin disease in patients with systemic lupus erythematosus. *Best. Pract. Res. Clin. Rheumatol.*; 16(2): 245- 264.
- Carroll M.C. (2000):** The role of complement in B cell activation and tolerance. *Adv. Immunol.*; 74: 61-88.
- Casciola-Rosen L., and Rosen A. (1997):** Ultraviolet light-induced keratinocyte apoptosis: A potential mechanism for the induction of skin lesions and autoantibody production in SLE. *Lupus*; 6: 175.
- Castellino G., Govoni M, Padovan M., Colamusi P., Borrelli M., and Trotta F. (2005):** Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients. *Ann. Rheum. Dis.* 64 (7): 1022-7.
- Castillo M. (2001):** Neuroimaging and cartography: Mapping brain tumors. *Am J Neuroradiol*, Apr; 22:597-598.

- Castillo M., Kwock L., Scatliff J. and Mukherji S. (1998):** Clinical applications of proton MR spectroscopy. *Am J Neuroradiol*, Jan; 17: 1-15.
- Chaves-Carballo, E.; Dalbagh, O. and Bahabris S. (1999):** Pseudomotor cerebri and leukoencephalopathy in childhood lupus. *Lupus*, 8: 81-84.
- Cheng, J. G., R. E. Mrak, C. R. Rovnaghi, E. Kozlowska, L. J. Van Eldik, and W. S. Griffin. (1999):** Human brain S100B and S100B mRNA expression increases with age: pathogenic implications for Alzheimer's disease. *Neurobiol. Aging* 17:359–36.
- Chiappa K.H. (1985):** Evoked potential in clinical medicine. 2nd edition. Raven Press, New York.
- Chin, R.L. and Latov, N. (2005):** Central nervous system manifestations of rheumatologic diseases. *Curr Opin. Rheumatol.*, 17: 91-99.
- Chinn RJ, Wilkinson ID, and Hall-Craggs MA.(1997):** Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. *Arthritis Rheum*; 40:36-46.

Chinn RJ, Wilkinson ID, and Hall-Craggs MA,(2000): Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. *Arthritis Rheum* 40:36-46

Coblyn J.S., and Weinblatt M.E. (1997): Rheumatic diseases and the heart. "SystemicLupus Erythematosus", In: Heart disease. " A textbook of cardiovascular medicine. Edited by: Braunwald E., 5th edition; Chap. 56: P. 1776.

Cohen M.R., and Isenberg D.A. (1996): Ultraviolet irradiation in systemic lupus erythematosus: Friend or foe? [Review] *Br. J. Rheumatol.*; 35: 1002.

Colamussi P, Trotta F, and Ricci R. (2000): Brain perfusion SPET and proton magnetic resonance spectroscopy in the evaluation of two systemic lupus erythematosus patients with mild neuropsychiatric manifestations. *Nucl Med Commun* : 18:269-273.

Cooper G.S., Dooley M.A., Treadwell E.L., and Clair E.W. (1998): Hormonal, Environmental, and infectious risk factors for developing systemic lupus erythematosus. *Arthritis& Rheum.*; 41 (10): 1714- 1724.

Cousins J.P. (1995): Clinical MR spectroscopy: Fundamentals, current applications, and future potential. *Am J Roentgenol*; 164: 1337-1347.

- Danielsen E.R. and Ross B. (1999):** Magnetic resonance spectroscopy diagnosis of neurological diseases. New York: marcel Dekker, -5-22.
- Degiorgio, L.A.; Konstantivo, K.N. and Lee, S.C. (2001):** A subset of lupus anti-DNA antibodies cross-reacts in systemic lupus erythematosus. Nat Med., 7: 1189-1193.
- Donadio J.V.Jr., and Glassock R.J. (1993):** Immunosuppressive drug therapy in lupus nephritis (review). Am. J. Kidney Dis.; 21: 239.
- Doninger, N.A.; Fink, J.W. and Utset, T.O. (2005):** Neuropsychologic functioning and health status in systemic lupus erythematosus: Does ethnicity matter. J Clin Rheumatol., 11: 25-256.
- Edworthy S.M. (2001):** "Clinical manifestations of systemic lupus erythematosus". In: Kelley's textbook of Rheumatology. Edited by: Ruddy S., Harris E.D., Sledge C.B. 6th edition.; Saunders, Philadelphia. Chap. 74: P. 1105-1123.
- Edworthy S.M. (2005):** Clinical manifestations of systemic lupus erythematosus. In: Kelley's textbook of rheumatology. Edited by: Harris E.D., Budd R.C., and Sledge C.B. 7th edition. Elsevier, Saunders. Chap. 75; P.1201.

Emori, A.; Matsushima, E.; Aihora, O.; Ohta, K.; Koime, R.; Miyasaka, N. and Kato, M. (2005): Cognitive dysfunction in systemic lupus erythematosus. *Psych Clin Neuroscience.*, 59: 584-589.

Euler H.H., Harten P., zeuner R.A., and Schwab V.M. (1997): "Recombinant granulocyte colony stimulating factor in patients with SLE, dissociated neutropenia and refractory infection". *J. Rheumatol.*; 24: 2153- 2157.

Esdaile J.M., Joseph L., and Abrahamowicz M. (1996): Routine immunologic tests in systemic lupus erythematosus: Is there a need for more studies? [See comments]. *J. Rheumatol.*; 23: 1891.

Euler H.H., Schroeder J.O., Harten P., and Zeuner R.A. (1994): Treatment- free remission in severe lupus erythematosus following synchronization of plasmapheresis with subsequent pulse cyclophosphamide. *Arthritis & Rheum.*; 37: 1784- 1794.

Fraenkel L., Mackenzie T., and Joseph L. (1994): Response to treatment as a predictor of longterm outcome in patients with lupus nephritis. *J. Rheumatol.*; 21: 2052.

- Friedman SD, Stidley CA, Brooks WM, and Sibbitt WL. (1999):** Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. *Radiology*; 209: 79-84.
- Friedman ,Stidley CA, Brooks WM, Hart BL, and Sibbit Jr WL.(2003):.** Brain injury and neurometabolic abnormalities in systemic lupus erythematosus. *Radiology* ; 209:79-84.
- Froelich J.W., Stephen A.K. and David A. (2003):** Standard for the performance and interpretation of magnetic resonance spectroscopy of the brain. *General Diagnostic Radiology*; 9:73-76.
- Funauchi, M., Ohno, M.; Nozaki, Y.; Sugiyama, M.; Kinoshita, K. and Kanamaru, A. (2003):** Intrathecal corticosteroids for systemic lupus erythematosus with central nervous system involvement. *J Rheumatol.*, 30: 207-208.
- Garton M.J., and Isenberg D.A. (1997):** Clinical features of lupus myositis versus idiopathic myositis: A review of 30 cases. *Br. J. Rheumatol.*; 36: 1067.
- Gazzolo, D., P. Vinesi, M. Bartocci, M. C. Geloso, W. Bonacci, G. Serra, K. G. Haglid, and F. Michetti.(1999):** Elevated S100 blood level as an early indicator of intraventricular hemorrhage in preterm infants. Correlation with cerebral Doppler velocimetry.; *J. Neurol. Sci.* 170:32–35.

- Gilboe I.M., Kvien T.K., and Husby G. (2001):** Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. *J. Rheumatol.*; 28: 266- 274.
- Gladman D.D., and Urowitz M.B. (1997):** " Systemic lupus erythematosus, clinical and laboratory features". *Primer on the Rheumatic Diseases*, 11th edition. Klippel J.H. (editor),Chap. 19: 215-257.
- Goncalves, D. S., G. Lenz, J. D. Karl, C. A. Goncalves, and R. Rodnight. (2000):** Extracellular S100B protein modulates ERK in astrocyte cultures.; *NeuroReport* 11:807–809.
- Graves E.E., Nelson S.T. and Vigneron D.B. (2001):** Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. *AJNR*; 22: 613-624.
- Griffiths D.J., Cooke S.P., and Herve C. (1999):** Detection of human retrovirus 5 in patients with arthritis and systemic lupus erythematosus. *Arthritis & Rheum.*; 42: 448.

Griffiths J.R. (1997): MRS in tumors-Clinical. Fifth scientific meeting of International Society for Magnetic Resonance in Medicine; Apr 12-18, (Vancouver BC, Canada); ISMRM Educational Course Syllabus, 321-328

Guglielmone H., Vitozzi S., Elbarcha O., and Fernandez E. (2001): Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Ann. Rheum. Dis.; 60: 500- 504.

Hachulla A.M., Klemp P., and Bates B. (1998): Avascular necrosis of the hip in systemic lupus erythematosus: the role of magnetic resonance imaging. Br. J. Rheumatol.; 32: 972-976.

Hahn B.H. (1998): Antibodies to DNA. N. Engl. J. Med.; 338(19): 1359- 1368.

Handa R, Sahota P, Kumar M, Jagannathan NR, Bal CS, Gulati M, and Wali JP. (2003) .In vivo proton magnetic resonance spectroscopy (MRS) and single photon emission computerized tomography (SPECT) in systemic lupus erythematosus (SLE). Magn Reson Imaging.; 21 (9): 1033-7.

Hang, L.M.; Izui, S. and Dixon, F.J. (1981): A model of acute lupus and coronary vascular disease with Myocardial infraction. J Exp Med., 36: 154-160.

Hanly J.G., Walsh N.M., Fisk J.D., Eastwoods B., and Hong C. (1993): cognitive impairment and autoantibodies in systemic lupus erythematosus. British J. of Rheumatol.; 32: 291- 296.

Hanly, J.G.; Fisk, J.D.; Sherwood, G.; Jones, E.; Jones, J.V. and Eastwood, B. (1992): Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol., 19: 562-567.

Hanly, J.G.; Walsh, N.M.; Fisk, J.D.; Eastwood, B., Hong, C.; Sherwood G.; Jones, J.V.; Jones, E. and Elkon, K. (1991): Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol., 32: 291-296.

Harley J.B., Moser K.L., and Gaffney P.M. (1998): The genetics of human systemic lupus erythematosus. Curr. Opin. Immunol.; 10: 690.

Harrison, M.J. and Ravidin, L.D. (2002): Cognitive dysfunction in neuropsychiatric systemic lupus erythmatosus. Curr Opin Rheumatol., 14 (5): 510-514.

- Haseley L.A., Wisnieski J.J., and Denburg M.R. (1997):** Antibodies to C1q in systemic lupus erythematosus: characteristics and relation to Fcγ RIIA alleles. *Kidney Int.*; 52: 1375.
- Hazleman B. (1997):** Musculoskeletal and connective tissue disease. In: "Textbook of Medicine ". 3rd ed. By: Souhami R.L. and Moxham J. Churchill, Livingstone.; Chap. 24: P. 912.
- Healy B.P., Scblant R.C., and Gonzalez E.B. (1994):** "The heart and connective tissue disease in the heart". By Hurst. Eighth edition. McGraw-Hill. Inc., New York, 1921-1935.
- Hehn K.F., and Peters M.S. (1993):** Deposition of membrane attack complex in cutaneous lesions of lupus erythematosus. *J. Am. Acad. Dermatol.*; 28(5): 687- 691.
- Hochberg M.C. (1997):** Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus (letter). *Arthritis & Rheum.*; 40: 1725
- Hornak J.P. (2002):** The basics of MRI, XII, Chap 4, 5 & 12.

Howe F.A., Barton S.J., Cudlip S.A., (2003): Metabolic profiles of human brain tumors using quantitative in vivo magnetic resonance spectroscopy .Magan .Rosen. Med. Feb.; 46; 223-32.

Iliopoulos A.G., and Tsokos G.C. (1996): Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin. Arthritis. Rheum.; 25: 318- 336.

Illei G.G., Austin H.A., and Crane M. (2001): combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med.; 135: 248- 257.

Ishimaru H., Nakashima K.,and Morikawa M., (2001): Improved diagnostic accuracy of contrast-enhancing brain lesions with recently developed MR techniques: diffusion-weighted image, perfusion image, and MR spectroscopy. Presented at the 39th annual meeting of the American Society Neuroradiology, Boston, April .

Jacos L, Kinkel PR, Costello PB, Alukal MK, and Green FA. (1999): Central nervous system lupus erthematosus: the value of magnetic resonance imaging. J Rheumatol 15: 60-1-606.

Jacobsen S., Petersen J., and Ullman S. (1998): A multicenter study of 513 Danish patients with SLE. II. Disease mortality and clinical factors of prognostic value. Clin. Rheumatol.; 17: 478.

Jarek MJ, West SG, Baker MR and , Rak KM. (2001):. Magnetic resonance imaging in systemic lupus erythematosus patients without a history of neuropsychiatric lupus erythematosus. Arthritis Rheum;37:1609-1613.

Jennekens, F.G.I. and Kater, L. (2002): The central nervous system in systemic lupus erythematosus: Part 2. Pathogenic mechanism of clinical syndromes: a literature investigation. Rheumatol., 41: 605-618.

Johnson, B. (1999): Systemic lupus erythematosus. *Am J Nurses.*, 99: 40-41.

Jolly C.A., Muthukumar A., and Avula C.P. (2001): Life span is prolonged in food-restricted autoimmune-prone (NZBXNZW) F (1) mice fed a diet enriched with (n-3) fatty acids. *J. Nutr.*; 131(10): 2753- 2760.

Jongen, P.J.H.; Boerbooms, A.M.T.; Lamers, K.J.B. and Rees, B.C. (1990): Diffuse CNS involvement in systemic lupus erythematosus: intrathecal synthesis of 4th component of complement. *Neurology*, 40: 1593-1596.

Jonsson, H., P. Johnsson, C. Alling, S. Westaby, and S. Blomquist.(2001): Significance of serum S100 release after coronary artery bypass grafting.; *Ann. Thorac. Surg.* 65:1639–1644.

Jorfen M., Callejas J.L. and Formiga F. (1998): Fulminant thrombotic thrombocytopenic purpura in systemic lupus erythematosus. *Scand. J. Rheumatol.*; 27: 76.

Julie, A.J.; Kovacs; Murray, B.;and Zeman, R. (1995): The use of SPECT in NPSLE. *J Rheumatol.*, 22: 1247-1252.

Kadota T., Horinouchi T., and Kuroda C. (2001): Development and aging of the cerebrum: assessment with proton MR spectroscopy. *AJNR*; 22: 128-135.

- Kalunian, K. C. (1997):** Definition, classification, activity and damage indices, p.19–29. In D. J. Wallace and B. H. Hahn (ed), Dubois' lupus erythematosus. Williams & Wilkins, Baltimore, Md.
- Karlson E.W., Daltory L.H., and Lew R.A. (1997):** the relationship of socioeconomic status, race, and modifiable risk factors to outcomes in patients with systemic lupus erythematosus. *Arthritis & Rheum.*; 40: 47.
- Kashihara K, Nakashima S, Kohira I, Shohmori T, Fujiwara Y, Kuroda S. (1998):** Hyperintense basal ganglia on T1-weighted MR images in a patient with central nervous system lupus and chorea. *AJNR Am J Neuroradiol*; 19:284-286.[
- Kaye, B.R.; Neuwelt, M.; London, S.S. and De Armond, S.J. (1992):** Central nervous system systemic lupus erythematosus mimicking progressive multifocal leucoencephalopathy. *Ann Rheum Dis.*, 51: 11825-1156.
- Keeling D.M., and Isenberg D.A. (1993):** Haematological manifestations of systemic lupus erythematosus [review]. *Blood Rev.*; 7: 199.
- Khamashta, M.A.; Cervera, R. and Hughes, G.R. (1991):** The central nervous system in systemic lupus erythematosus. *Rheumatol Int.*, 11: 117-119.

Kienlin M. Von (1999): Basic magnetic resonance spectroscopy and localization methods. 16th annual scientific meeting of Europ. Soc. For MR in Medicine and Biology (ESMRMB) September; 3-27.

Klippel J.H. (1997): " Systemic Lupus Erythematosus: Treatment." Primer on the Rheumatic Diseases, 11th edition; 258-261.

Kotzin B.L., and O'Dell J.R. (1995): Systemic lupus erythematosus. In Frank M.M., Austen K.F., Claman H.N., and Unanue E.R. (eds.): Samter's Immunologic Diseases, 5th ed. Boston, Little, Brown &Co., P. 667-697.

Kovacs, B.; Lafferty, T.L.; Brent, L. and De Horatius, R.J. (2000): Transverse myelopathy in systemic lupus erythematosus: An analysis of 14 cases and review of the literature. Ann Rheum Dis., 59: 120-124.

Kozora E , David B A, Lening Z and Sterling W, (2007): .Neuropsychological patterns in systemic lupus erythematosus patients with depression. Arthritis Research & Therapy, 9:R48

Kron, J.; Hamper, U.M.; and Petri, M. (2001): Prevalence of cerebral micro emboli in systemic lupus erythematosus: transcranial Doppler. J Rheumatol., 28: 2222-2225.

- Kushner, M.J.; Tobin, M. and Fazekas (1991):*** Cerebral blood flow variation in CNS lupus. *Neurology*, 40: 99-102.
- Lamers, K. J., B. G. van Engelen, F. J. Gabreels, O. R. Hommes, G. F. Borm, and R. A. Wevers.(1999):*** Cerebrospinal neuron-specific enolase, S-100 and myelin basic protein in neurological disorders.; *Acta Neurol. Scand.* 92:247–251.
- Langman M.J., Jensen D.M., and Watson D.J. (1999):*** Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. *JAMA*; 282: 1929.
- Liang, H.L.; Socher, S.A.and Larson, M.A. and Schur, P.H. (1989):*** Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus arthritis Rheum., 32; 1107-1118.
- Liem, M.D.; Gzesh, D.J and Flanders, A.E. (1996):*** MRI and angiographic diagnosis of lupus cerebral vasculitis. *Neuroradiology*, 38: 134-136.
- Lin J.W. and Wolinsky S.J. (2005):*** American College of Physicians (ACP)medicine, section 11 neurology, IX demyelinating disease.

- Magid M.S., Kaplan C., and Sammaritano L.R. (1998):** Placental pathology in systemic lupus erythematosus: A prospective study. *Am. J. Obstet. Gynecol.*; 179: 226.
- Mandell B.F., and Hoffman G.S. (2001):** Rheumatic diseases and the cardiovascular system. In: "Heart disease". A textbook of cardiovascular medicine. 6th ed., W.B. Saunders Company.; Chap.67: P. 2199.
- Manger K., Repp R., and Spriewald B.M. (1998):** Fcγ receptor IIA polymorphism in Caucasian patients with systemic lupus erythematosus: Association with clinical symptoms. *Arthritis & Rheum.*; 41: 1181.
- Maric, D.; Millward, J. M.; Ballok, D.A.; Szechtman, H.; Denbury J. A. and Barker, J.L. (2001):** Neurotoxic properties of cerebrospinal fluid from behaviorally impaired autoimmune Mice. *Brain Resuscitation*, 920: 183-193.
- McCune, W.J.; Mc Cuine, A.; Aisen, A. and Gebarski, E. (1988):** Identification of brain lesions in neuropsychiatric systemic lupus erythematosus by magnetic resonance imaging. *Arthritis. Rheum.*, 31: 159-166.
- McDonagh J.E., Khamashta M.A., and Menon S. (1997):** A young woman with SLE: Diagnostic and therapeutic challenges. *Lupus*; 6: 633.

- McGrath H.Jr. (1994):** Ultraviolet-A1 irradiation decreases clinical disease activity and autoantibodies in patients with SLE. Clin. Exper. Rheumatol.; 12: 129.
- Meyerand M.E., Pipas J.M., and Niamourian A. (1999):** Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy. Am J Neuroradiol, Jan; 20(1): 117-123.
- Mitchell, I.; Webb, M.; Hughes, R.; Malsey, M. and Cameron, S. (1994):** Cerebral lupus. Lancet, 343: 579-582.
- Moder K.G., Miller T.D., and Tazelaar H.D. (1999):** Cardiac involvement in systemic lupus erythematosus. Mayo. Clin. Proc.; 74(3): 275- 284.
- Mok C.C., Ho C.T., and Chan K.W. (2002):** Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis & Rheum.; 46: 1003- 1013.
- Moore, P.M. (1999):** Neuropsychiatric systemic lupus erythematosus. In: Iahita R.G. edn. Systemic lupus erythematosus. Third edition. San Diego C.A: Academic press: 575-601.

Murphy P.S., Viniers L. and Abson C. (2004): monitoring temozolomide treatment of low grade glioma with proton magnetic resonance spectroscopy. Br. J. Cancer. February; 23;90(4):781-6.

Myung Kwan Lim, MD, Chang Hae Suh, MD, Hyung Jin Kim, MD, Young Kook Cho, MD, Seung Ho Choi, MD, Jee Hee Kang, MD, Won Park, MD and Jung Hee Lee, PhD.(2000): Systemic Lupus Erythematosus: Brain MR Imaging and Single-Voxel Hydrogen 1 MR Spectroscopy. Radiology;217:43-49.

Neuwelt C.M., Lacks S., KayeB.R. and Borenstein D.G. (1995): Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am. J. Med.; 98: 32- 41.

Nomura, K., S. Yamano, Y. Ikeda, H. Yamada, T. Fujimoto, S. Minami, R. Fukui, M. Takaoka, Y. Yamamoto, and K. Dohi. (2002):. Asymptomatic cerebrovascular lesions detected by magnetic resonance imaging in patients with systemic lupus erythematosus lacking a history of neuropsychiatric events. Intern. Med. **38**:785–795.

- Ochola, J.; Hussain, M.; Khamashta, M.; Hughes, G.R and Vergani, D. (1995):** Detection of brain-reactive autoantibodies in the sera of patients with systemic lupus erythematosus and cerebral involvement. *J. Immunol Meth.*, 185: 259-261.
- Ostensen M., and Villiger P.M. (2001):** Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. *Lupus*; 10(3): 135- 139.
- Peeva E., Diamond B., and Putterman C. (2002):** Immunoglobulins and autoantibodies. In: Wallace D.J. and Hahn B.H. (eds): *Dubois' Lupus Erythematosus*, 6th ed., Philadelphia, lippincott, Williams and Wilkens. P. 391-415.
- Petri M. (1995):** Clinical features of systemic lupus erythematosus (review). *Curr. Opin. Rheumatol.*; 7: 395.
- Petri M. (2002):** Clinical and management aspects of antiphospholipid syndrome. In: Wallace D.J. and Hahn B.H. (eds): *Dubois' Lupus Erythematosus*, 6th ed., Philadelphia, Lippincott, Williams and Wilkens. P.1093.
- Pisetsky D.S. (1997):** " Systemic Lupus Erythematosus" : A. Epidemiology, Pathology, and Pathogenesis. In: *Primer on the Rheumatic Diseases*. 11th ed. By: Klippel J.H. (Editor). Atlanta, Georgia: Chapter (19): P. 246.

Pryor B.D., Bologna S.G., and Kahl L.E. (1996): Risk factors for serious infection during treatment with cyclophosphamide and high-dose corticosteroids for systemic lupus erythematosus. *Arthritis & Rheum.*; 39: 1475.

Quintero-Del-Rio, A.I. and Van, M. (2000): Neurologic symptoms in children with systemic lupus erythematosus. *J Child Neurol.* 5: 803-807.

Rahman P., Gladman D.D., and Urowitz M.B. (1998): Clinical predictors of fetal outcome in systemic lupus erythematosus. *J. Rheumatol.*; 25: 1526.

Ramsey-Goldman R., and Manzi S. (2001): Association of osteoporosis and cardiovascular disease in women with systemic lupus erythematosus. *Arthritis & Rheum.*; 44(10): 2338- 2341.

Ravirajan C.T., Rahman M.A., and Papadaki L. (1998): Genetic, structural and functional properties of an IgG DNA-binding monoclonal antibody from a lupus patient with nephriti. *Eur. J. Immunol.*; 28: 339.

Remer C.F., Weisman M.H., and Wallace D.J. (2001): Benefits of leflunomide in systemic lupus erythematosus: A pilot observational study. *Lupus*; 10(7): 480- 483.

Richter C.M., Steiner G., Smolen J.S., and Isenberg D.A. (1998):

Erosive arthritis in systemic lupus erythematosus:
Analysis of a distinct clinical and serological subset. Br.
J. Rheumatol.; 37: 421.

Rioux J.D., Zdarsky E., and Newkirk M.M.(1995): Anti-DNA and

anti-platelet specificities of SLE-derived autoantibodies:
Evidence for CDR2H mutations and CDR3H motifs.
Mol. Immunol.; 32: 683.

Robbins, M.L.; Kornguth, S.E. and Bell, C.L. (1988):

Antineurofilament antibody evaluation in
neuropsychiatric systemic lupus . Arthritis Rheum., 31:
623-628.

Rothfield N.F. (1989): " SystemicLupus Erythematosus: Clinical

aspects and treatment". In: Arthritis and Allied
conditions. A textbook of Rheumatology. McCarty
D.J.(ed.), 9th edition; Philadelphia; P. 131.

Rothfield N.F. (1993): " SystemicLupus Erythematosus: Clinical

aspects and treatment". In: Arthritis and Allied
conditions. A textbook of Rheumatology. McCarty D.J.
(ed.), 12th edition; Philadelphia; P. 1155- 1177.

Ruiz-Irastorza G., Khamashta M.A., and Hunt B.J. (2002): Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. *Arch. Intern. Med.*; 162: 1164- 1169.

Sabbadini, M. G., A. A. Manfredi, E. Bozzolo, L. Ferrario, C. Rugarli, R. Scorza, L. and A. Passaleva. (1999). Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. *Lupus* 8:11–19.

Sabet, A.; Sibbit, W.; Stidley, C.A.; Danska, J and Brooks W.M. (1998): Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. *Stroke*, 29: 2254-2260.

Salmon J.E. (2002): Abnormalities in immune complex clearance and Fcγ receptor function. In: Wallace D.J. and Hahn B.H. (eds): *Dubois' Lupus Erythematosus*, 6th ed., Philadelphia, lippincott, Williams and Wilkens. P. 219-242.

Salmon J.E., and Kimberly R.P. (2000): " Systemic Lupus Erythematosus" In: Manual of Rheumatology and outpatient orthopedic disorders. "Diagnosis and therapy". 4th edition. Paget S.A., Gibofsky A., and Beery J.F. (editors): 236- 251.

Sanchez-Guerrero J., Karlson E.W., Liang M.H., and Hunter D.J. (1997): Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Arthritis & Rheum.; 40(5): 804- 808.

Sanchez-Guerrero J., Liang M.H., Karlson E.W., and Hunter D.J. (1995): Postmenopausal estrogen therapy and the risk of developing systemic lupus erythematosus (SLE). Ann. Intern.Med.; 122: 430- 433.

Sang-Cheol, B. (2003): The ACR classification of neuropsychiatric systemic lupus erythematosus: how this helps in diagnosis and treatment. APLAR J Rheumatol., 6: 188- 191.

Sanna, G., M. Piga, J. W. Terryberry, M. T. Peltz, S. Giagheddu, L. Satta, A. Ahmed, A. Cauli, C. Montaldo, G. Passiu, J. B. Peter, Y. Shoenfeld, and A. Mathieu. (2000): Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations.; *Lupus* 9:573–583.

Sanna, G.; Bertolaccini, M.L.; Cuadrado, M.J.; Laing, H.; Khamashta, M.A.; Mathieu, A. and Hughes, G.R. (2005): neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. *J Rheumatol.*, 30 (5): 985-992.

Sato E.I. (2001): methotrexate therapy in systemic lupus erythematosus. *Lupus*; 10(3): 162- 164.

Schur P.H. (1989): "Clinical features of systemic lupus erythematosus. ". In: *Kelley's Textbook of Rheumatology*, 3rd edition. By: Kelley W.N., Harris E.D., Ruddy S., and Sledge C.B.(eds.); W.B. Saunders Company, Philadelphia.; P. 1101- 1129.

Schur P.H.(1993): "Clinical features of systemic lupus erythematosus. ". In: Kelley's Textbook of Rheumatology, 4th edition. By: Kelley W.N., Harris E.D., Ruddy S., and Sledge C.B.(eds.); W.B. Saunders Company, Philadelphia, London, Toronto. Chap. 61: P. 1030- 1039.

Scolding, N.J. and Joseph, F.G. (2002): The neuropathology and Pathogenesis of systemic lupus erythematosus. Neuropathology and Applied Neurobiology, 28: 173-189.

Seal S.N., Hoet R.M., Raats J.M., and Radic M.Z. (2000): Analysis of autoimmune bone marrow by antibody-phage display: Somatic mutations and third complementarity-determining region arginines in anti- DNA gamma and Kappa genes. Arthritis & Rheum.; 43(9): 2132- 2138.

Shellock F.,G.(2001): Magnetic resonanse procedures: health effects and safty. Boca Raton, FLA:CRC PRESS.

Sillevis, S.P.; Kinoshita, A. and De-Leeuw, B. (2000): Paraneoplastic cerebella ataxia due to autoantibodies against glutamate receptor. N Eng J Med., 342: 21-27.

Sjowall C., Eriksson P., Almer S., and Skogh T. (2002): autoantibodies to C- reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J. Autoimmun.; 19: 155- 160.

Smith, R.W.; Ellison, D.w.; Jenkins, E. A.; Gallagher, P.J. and Caweliy, M.I.D. (1994): Cerebellum and brainstem vasculopathy in systemic lupus erythematosus: Two Clinico-pathological cases. Ann Rheum Dis., 53: 327-330.

Sontheimer R.D. (1996): Photo-immunology of lupus erythematosus and dermatomyositis: A speculative review. Photochem. Photobiol.; 63: 583.

Speck O, J Hennig and T. Thiel (1997): Improved sensitivity to overlapping multiplet signals in vivo proton spectroscopy using multiecho volume selective (CPRESS) experiment magnetic resonance in medicine ;37:816.

Steinberg A.D. (1992): " concepts of pathogenesis of SLE". Clin. Immunol. Immunopathol.; 63(1): 19-25.

- Suarez- Almazor M.E., Gonzales- Lopez J., and Gamez- Nava I. (1998):** Utilization and predictive value of laboratory tests in patients referred to rheumatologists by primary care physicians.; J. Rheumatol.; 25: 1980.
- Taccari E, Sili Scavalli A, Spadaro A, Riccieri V, Trasimeni G, Di Biasi C, and Gualdi GF. (2002):** Magnetic resonance imaging (MRI) of the brain in SLE: ECLAM and SLEDAI correlations. Clin Exp Rheumatol. :12(1):23-8.
- Talar-Williams C., Hijazi Y., and Walther M. (1996):** Cyclophosphamide- induced bladder toxicity in patients with Wegener's granulomatosis. Ann. Intern. Med.; 124: 477- 484.
- Tan E.M., Cohen A.S. and Fries J.F. (1982):** The 1983 revised criteria for classification of SLE. Arth. Rheum. 25: 1271: 77.
- Tan E.M., Feltkamp T.E.W., Smolen J.S., and Butcher B. (1997):** Range of antinuclear antibodies in "healthy" individuals. Arthritis & Rheum.; 40(9): 1601- 1611.
- Tan E.M., Smolen J.S., McDougal J.S., and Butcher B.T. (1999):** A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. "I. Precision, sensitivity, and specificity". Arthritis & Rheum.; 42(3): 455- 464.

- Taskos, G.C. (2001):** Systemic lupus erythematosus: A disease with a complex pathogenesis. *Lancet*, 358 (Supple). S65.
- Terregino, C.A. (1999):** Systemic lupus erythematosus. University medical centre, 1-11. Retrieved February 25, 2002, from midline search.
- Trysberg, E. and Tarkowski, A. (2004):** Cerebral inflammation and degeneration in systemic lupus erythematosus. *Curr Opin Rheumatol.*, 16: 527-533.
- Trysberg, E.; Carlsten, H. and Tarkowski A. (2000):** Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. *Lupus*, 9: 498-503.
- Tsao B.P. (2002):** An update on genetic studies of systemic lupus erythematosus. *Curr. Rheumatol. Rep.*; 4(4): 359- 367.
- Tsao B.P., Cantor R.M., and Grossman J.N. (1999):** PARP alleles within the linked chromosomal region are associated with systemic lupus erythematosus. *J. Clin. Invest.*; 103: 1135.
- Urowitz M.B., Gladman D.D., Abushakra M., and Farewell V.T. (1997):** Mortality studies in systemic lupus erythematosus. Results from a single center III. Improved survival over 24 years. *J. Rheumatol.*; 24: 1061.

Virgil L., and Woods J.R. (1993): Pathogenesis of SLE. In: "Textbook of Rheumatology". 4th edition. By: Kelley W.N., Harris E.D., Ruddy S., and Sledge C.B.; W.B. Saunders Company, Philadelphia, London, Toronto. Chap. 60: P. 999.

Walker L.S., and Abbas A.K. (2002): The enemy within: Keeping self- reactive T cells at bay in the periphery. Nat. Rev. Immunol.; 2(1): 11- 19.

Wallace D.J. (2002): Principles of therapy and local measures. In: Wallace D.J. and Hahn B.H. (eds): Dubois' Lupus Erythematosus, 6th ed., Philadelphia, Lippincott, Williams and Wilkens. P.1131.

Wallace D.J., and Metzger A.L. (1997): Systemic Lupus Erythematosus: Clinical aspects and treatment. In: Arthritis and allied conditions: A textbook of rheumatology. Edited by: William J. Koopman, and Daniel J. McCarty. 13th edition. Chap. 69; P. 1319.

Walz LeBlanc B.A., Dagenais P., and Urowitz M.B. (1994): Methotrexate in systemic lupus erythematosus. J. Rheumatol.; 21: 836.

Wang B., Gladman D.D., and Urowitz M.B. (1998): Fatigue in lupus is not correlated with disease activity. J. Rheumatol.; 25: 892.

- Wang Z, Zimmerman RA and Sauter R.(1999):** Proton MR spectroscopy of the brain: clinically useful information obtained in assessing CNS diseases in children. *AJR Am J Roentgenol* 167:191-199.
- Wang C., Mayo N., and Forlin P. (2001):** The relationship between health related quality of life and disease activity and damage in systemic lupus erythematosus. *J. Rheumatol.*; 28: 525- 532.
- Ward M.M., Pyun E., and studenski S. (1995):** Causes of death in systemic lupus erythematosus: Long term follow up of an inception cohort. *Arthritis & Rheum.*; 38(10): 1492-1499.
- Waterloo, K.; Omdal, R.; Sjöholm, H.; Koldingseus, W.; Jacobsen, E.A. and Sundsfjord, J.A. (2001):** Positron emission tomography and magnetic resonance imaging for cerebral involvement in patients with systemic lupus erythematosus. *J. Neurol.*, 248: 595-602.
- Werth V.P., Dutz J.P., and Sontheimer R.D. (1997):** Pathogenetic mechanisms and treatment of cutaneous lupus erythematosus (review). *Curr. Opin. Rheumatol.*; 9: 400.
- West, S.G. (1994):** Lupus and the central nervous system. *Curr Opin Rheumatol.*, 8: 408-414.

- West SG, Emlen W, Wener MH and Kotzin BL. (1995):** Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. *Am J Med*; **99**:153–63.
- Winfield, J.B.; Brunner, C.M. and Koffler, D. (1978):** Serologic studies in patients with systemic lupus erythematosus and central nervous system dysfunction. *Arthritis Rheum.*, 21: 289-294.
- Winslow T.M., Ossipov M.O., Fazio G.P., and Simonson J.S. (1995):** Five- year follow- up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. *Am. Heart J.*; 129: 510- 515.
- Wolf, J.; Niedermayer, N.; Bergner, R. and Lowitzsch, K. (2001):** Cerebral vasculitis as the initial manifestation of systemic lupus erythematosus. *Dtsch Medical Wochenschr*, 126: 947-950.
- Wu J., Edberg J.C., and Redecha P.B. (1997):** A novel polymorphism of FcγRIIIa (CD 16) alters receptor function and predisposes to autoimmune diseases. *J. Clin. Invest.*; 100: 1059.
- Wyllie, M.K. (2002):** Lupus cerebritis: A case study. *Journal of Neuroscience Nursing*, 34 (4): 176-183.